Title : BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia.

Pub. Date : 2021 Feb 2

PMID : 33540760






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 RESULTS: AML cell lines were variably susceptible to PTC596 and to combination treatments with PTC596 and MCL1 inhibitor S63845, MEK inhibitor trametinib, or TP53 activator APR-246, independent of TP53 mutational status. S63845 MCL1 apoptosis regulator, BCL2 family member Homo sapiens
2 CONCLUSIONS: The combination of PTC596 and S63845 may be an effective treatment in CD34+ adverse risk AML with elevated MN1 gene expression and MCL1 protein levels, while PTC596 and trametinib may be more effective in CD34+ adverse risk AML with elevated BMI1 gene expression and MEK protein levels. S63845 MCL1 apoptosis regulator, BCL2 family member Homo sapiens